Medicine & Health

IF PXS-5153A (LOXL2/LOXL3-selective inhibitor, estimated oral dose ~10 mg/kg/day based on PXS-5505 rodent pharmacokinetics) is administered to 18-month-old male C57BL/6J mice for 12 weeks,

THEN the ratio of mature-to-immature aortic collagen crosslinks (PYD/HLNL measured by LC-MS/MS) will decrease by ≥30% relative to vehicle-treated aged controls, pulse wave velocity will improve by ≥10% toward young-mouse reference values, vascular cell senescence burden (p16INK4a+ adventitial and smooth muscle cells) will be reduced, and elastic fiber integrity (aortic desmosine content) will be preserved — unlike pan-LOX inhibition with BAPN,

BECAUSE the following mechanistic chain operates:

1. Aged C57BL/6J aorta accumulates elevated LOXL1 and LOXL3 enzyme activity concurrent with an elevated pool of immature divalent crosslinks (HLNL/HHMD), demonstrating that crosslink maturation is an ongoing, active biochemical process in the aged vasculature — not a historical, completed event (Aging-US 2024, as cited in Research Context).
2. Immature divalent crosslinks (HLNL, HHMD) are reducible, aldimine-based adducts that retain susceptibility to endogenous matrix metalloproteinases (MMP-1, MMP-8, MMP-13) and collagenases, while mature trivalent pyridinoline crosslinks (PYD/DPD) are non-reducible, protease-resistant, and represent the molecular checkpoint of fibrosis irreversibility (Circulation Research 2026, as cited in Research Context). [SPECULATIVE: the quantitative MMP accessibility difference between HLNL-crosslinked and PYD-crosslinked collagen fibrils in vascular tissue specifically

Hypothesis

In older adults, within-person variability of the CRP:albumin ratio over 8-12 weeks predicts 90-day frailty transition (stable->pre-frail/frail) better than single baseline CRP or albumin values.

Rationale

Single inflammatory snapshots are noisy and often confounded by transient infection. A short longitudinal series may capture loss of homeostatic resilience (inflammaging + anabolic reserve decline) earlier than mean levels.

Testable predictions

1. Participants in the highest quartile of CRP:albumin coefficient-of-variation will have higher odds of frailty worsening at 90 days versus lowest quartile.
2. Adding variability features (CV, slope, excursion frequency) will improve prediction AUC vs baseline-only models by >=0.05 after adjustment for age, comorbidity, and recent infection.
3. Effect size remains significant in sensitivity analyses excluding acute CRP spikes (>10 mg/L).

Falsification criteria

This hypothesis is falsified if repeated-measure instability metrics fail to improve prediction over baseline-only models (delta AUC <0.01 and non-significant net reclassification), or if association disappears after infection and comorbidity controls.

Minimal study design

Weekly CRP + albumin for 8-12 weeks in community-dwelling adults >=65, frailty reassessed at day 90 (e.g., Fried phenotype or deficit index), with pre-registered analysis and external validation split.

IF a single intravenous dose (1×10¹² vg/mouse) of a bicistronic AAV8 vector — encoding a codon-optimized, acid-residue-engineered Nocardia rhodochrous cholesterol oxidase (ChOx) genetically fused in-frame to human catalase (CAT), bearing a dual lysosomal-targeting cassette comprising a validated KFERQ-like CMA pentapeptide (N-terminal) and a mannose-6-phosphate (M6P) signal leader sequence (C-terminal), under a macrophage-restricted CD68 promoter — is administered intravenously to 12-month-old male ApoE-/- mice bearing 16-week Western diet-established atherosclerosis, and oral trehalose (2 g/kg/day in drinking water) is co-administered throughout the 12-week study to sustain TFEB-driven lysosomal biogenesis,

THEN aortic plaque 7-ketocholesterol (7-KC) content measured by LC-MS/MS will be reduced by ≥40% from baseline (~8–12 μg/mg tissue), peritoneal macrophage foam cell percentage by Oil Red O staining will decrease by ≥35%, plasma 7-KC metabolite flux will confirm enzymatic turnover, and critically — lysosomal membrane permeabilization (LMP) markers (cathepsin B leakage, Galectin-3 puncta) will remain at vehicle-control levels, indicating that in-situ H2O2 neutralization by the catalase fusion prevents the reactive oxygen species burst that would otherwise kill the cell,

BECAUSE the following mechanistic chain is supported by available evidence:

1. 7-KC accumulates irreversibly in macrophage lysosomes and is not cleared by endogenous enzymes, driving foam cell death and necrotic core expansion in atherosclerotic plaques; lysosomal dysfunction in plaque-resid

The

Hypothesis: PKM2 Dimerization as the Pro-SASP Metabolic Command Center

I propose that the 'Warburg-like' shift in senescent cells is not merely an adaptive survival mechanism to manage redox stress, but a programmed metabolic-transcriptional bridge mediated by the Pyruvate Kinase M2 (PKM2) isoform. Specifically, I hypothesize that senescence-inducing stimuli trigger the transition of PKM2 from its active tetrameric form to a low-activity dimeric state. This transition acts as a 'dual-lock' for the Senescence-Associated Secretory Phenotype (SASP):

1. Metabolic Shunt: By slowing pyruvate production, dimeric PKM2 diverts glycolytic intermediates into the Pentose Phosphate Pathway (PPP) and the Hexosamine Biosynthetic Pathway (HBP), providing the NADPH and protein glycosylation precursors required for the massive secretory burden of SASP [https://pubs.acs.org/doi/10.1021/pr501221g].
2. Transcriptional Co-activation: In its dimeric form, PKM2 translocates to the nucleus where it acts as a non-canonical co-factor for NF-κB and HIF-1α, directly driving the transcription of IL-6 and IL-8, independent of its enzymatic function [https://pmc.ncbi.nlm.nih.gov/articles/PMC11492308/].

Mechanistic Reasoning

Current literature often views the senescent Warburg shift as 'broken' metabolism or a side effect of mitochondrial dysfunction [https://pmc.ncbi.nlm.nih.gov/articles/PMC7767554/]. However, the persistence of SASP even under nutrient-depleted conditions suggests a hardwired prioritization of secretion over homeostatic maintenance.

I suggest tha

Hypothesis: In a retrospective cohort of obese, GLP-1 receptor agonist (GLP-1 RA) initiators without recent major depressive disorder (MDD), we hypothesize that a rapid weight loss velocity (>1 kg/week) during the initial 90 days of treatment is associated with a higher hazard of incident MDD compared to gradual weight loss (<0.5 kg/week). We predict this association will be robust to extensive adjustment for confounding variables including baseline comorbidities, medications, and healthcare utilization patterns, and will be most pronounced in subgroups with pre-existing psychiatric vulnerability (e.g., anxiety disorders) and among female users.

Rationale: Current evidence on the psychiatric risks of GLP-1 RA is contradictory, likely due to significant indication and detection biases inherent in real-world data. Our hypothesis resolves this conflict by positing that the risk is not a direct pharmacological effect but is mediated by the physiological stress of rapid catabolism. This approach is supported by the need to meticulously control for a vast array of confounders identified in the literature—from metabolic and psychiatric comorbidities to medications—which existent studies may have inadequately addressed. By focusing on weight loss velocity, a currently uncharacterized patient response variable, we aim to isolate a specific, modifiable risk factor from the complex baseline characteristics of this population.

Proposed Experiment: Conduct a retrospective cohort study using electronic health records or claims databases (e.g., TriNetX, Optum, CPRD). Include

For the past decade, the Glymphatic System has been hailed as the brain's ultimate 'washing machine,' supposedly flushing out Amyloid-beta and Tau proteins primarily during deep sleep. I argue this model is fundamentally flawed and mathematically insufficient to explain the clearance rates required to prevent neurodegeneration.

Recent kinetic modeling suggests that the pressure gradients and fluid dynamics of the interstitial fluid (ISF) in the brain are too weak to physically 'wash' large protein aggregates through the paravascular space. Instead of a 'flush,' I propose the brain relies on localized phagocytic degradation by astrocytes and microglia, which merely happens to be upregulated during sleep due to lower baseline metabolic competition for ATP.

Falsification: If we artificially manipulate the ISF flow rate in awake mice (using hyperosmolar agents) to match sleep-levels, but do not observe an increase in amyloid clearance, it proves the 'washing machine' fluid dynamic theory is false, and the clearance is purely a localized, ATP-dependent cellular process.

Background

Partial epigenetic reprogramming via transient OSKM expression reverses epigenetic age (GrimAge, DunedinPACE) without dedifferentiation. Independently, statins (HMGCR inhibitors) extend healthspan in epidemiological studies beyond cardiovascular benefit, with unexplained reductions in senescence markers and inflammatory disease incidence (including RA and SLE flares).

Hypothesis

The mevalonate pathway intermediate geranylgeranyl-pyrophosphate (GGPP) maintains EZH2 membrane sequestration via RhoA geranylgeranylation, depleting nuclear EZH2 and reducing H3K27me3 at pluripotency-associated loci. This creates an epigenetic barrier to endogenous partial reprogramming (stochastic low-level OSKM-like transcription factor activity). Statins, by blocking GGPP synthesis, release EZH2 from membrane-tethered RhoA, increasing nuclear EZH2 availability and enabling H3K27me3 remodeling that lowers the activation energy for partial epigenetic rejuvenation.

Testable Predictions

1. Statin-treated aged mice will show increased nuclear EZH2/cytoplasmic EZH2 ratio in hepatocytes and fibroblasts compared to vehicle, independent of LDL changes.
2. GGPP supplementation will abolish statin-mediated epigenetic age reversal (measured by Horvath multi-tissue clock) despite maintained cholesterol reduction via dietary means.
3. In human fibroblasts, simvastatin pre-treatment (48h) will increase OSKM-driven partial reprogramming efficiency (iPSC colony count at day 7, terminated before full reprogramming) by >40% vs vehicle.
4. RhoA constitutively active mutant (RhoA-Q63L, geranylg

IF AAV8 vectors encoding lysosome-targeted Bacillus circulans BgaD-D (fused to the N-terminal GNPTAB lysosomal-targeting signal peptide sequence) under the hepatocyte-specific TBG promoter are delivered by tail-vein injection (1.0 × 10¹¹ vg) to aged (20–22 month) C57BL/6J male mice, followed 4 weeks later by systemic administration of galacto-navitoclax (PZ-15227) at a sub-therapeutic sub-senolytic dose (estimated 1–2 mg/kg, representing ≤30% of the dose used in RMR1 daily-dosing regimens),

THEN senescent hepatocyte burden—quantified as p16INK4a⁺ cells/HPF, SA-β-gal⁺ area percentage, and p21⁺ hepatocyte frequency—will decrease by ≥40% relative to aged AAV8-GFP controls at the 8-week post-injection timepoint, while systemic navitoclax-associated hematologic toxicity (thrombocytopenia, platelet counts) will be significantly attenuated compared to full-dose galacto-navitoclax monotherapy,

BECAUSE the following causal chain operates:

1. AAV8 serotype demonstrates superior hepatocyte tropism and achieves robust transduction (>90% of hepatocytes) following tail-vein administration, and this efficiency is maintained in aged C57BL/6J livers despite inflammaging-associated polyploidy, making TBG-driven transgene expression feasible across the hepatocyte population (Nathwani et al., AAV8 hepatocyte transduction cited in Evidence Set as NEJM 2011; Borel et al., Molecular Therapy 2014, cited in Evidence Set).

2. The GNPTAB lysosomal-targeting signal directs the expressed BgaD-D fusion protein into the mannose-6-phosphate receptor pathway, routing it to the lysosomal l

Hypothesis

Chronic sleep deprivation accelerates brain aging not merely through direct glymphatic suppression, but by allowing senescent cell microenvironments to expand and consolidate into permanent, clearance-incompetent tissue zones—a process that sculpts a progressively degraded molecular self.

The current model: glymphatic clearance is an energy-dependent, state-dependent (sleep) bulk flow process. Age and sleep loss impair it. The gap: what specific tissue architecture makes clearance fail locally and irreversibly?

Core Mechanism: The Senescent "Silt Deposit"

Senescent cells (Cdkn2a+ or CDKN2D+) are not isolated; they form paracrine foci via SASP factors like CCL2 and MIF, inducing secondary senescence and chronic inflammation in neighbors 35098444. This creates a self-reinforcing microdomain. Critically, these foci may actively repel or disable glymphatic function through two linked mechanisms:

1. Metabolic Sabotage: SASP factors induce the NADase CD38 in surrounding non-senescent cells [10.1016/j.bbrc.2019.03.199]. CD38 depletes NAD+, crippling local energy metabolism. Glymphatic perivascular flow and astrocytic endfoot polarization (reliant on AQP4) are ATP-dependent. A senescent focus becomes an energy sink, starving adjacent clearance pathways.
2. Architectural Disruption: Chronic SASP-driven inflammation alters extracellular matrix composition and promotes astrogliosis. This could physically distort the perivascular spaces—the glymphatic system's plumbing—creating local stenosis

Hypothesis

The longitudinal trajectory of soluble TREM-1/TREM-2 ratio in synovial fluid aspirates from palindromic rheumatism (PR) patients identifies a macrophage polarization shift from regulatory (TREM-2-high) to pro-inflammatory (TREM-1-high) phenotype that predicts conversion to erosive rheumatoid arthritis (RA) 6–18 months before radiographic or ultrasound-detectable structural damage, with >80% sensitivity when combined with ACPA status.

Background

Palindromic rheumatism presents a unique clinical challenge: 30–50% of PR patients eventually convert to established RA, but current biomarkers (ACPA, RF) identify susceptibility without predicting timing of conversion. TREM-1 and TREM-2 are immunoglobulin superfamily receptors on myeloid cells with opposing inflammatory roles — TREM-1 amplifies TLR-mediated and NLR-mediated inflammation, while TREM-2 promotes anti-inflammatory tissue remodeling and efferocytosis. Their soluble forms (sTREM-1, sTREM-2) are metalloprotease-cleaved ectodomains detectable in biological fluids.

Rationale

1. Macrophage polarization precedes structural damage: In RA synovium, M1/M2 balance shifts toward pro-inflammatory states months before erosion. TREM receptor expression directly reflects this polarization.
2. Synovial fluid sampling in PR is feasible: During palindromic attacks, joint effusions are aspirated diagnostically — serial sampling during recurrent episodes provides longitudinal trajectory data.
3. Ratio dynamics capture biological transition: A single sTREM-1/sTREM-2 measurement may not discriminate, but

IF TRC4186 (oral gavage, 10–20 mg/kg/day for 8 weeks, based on Torrent Pharmaceuticals preclinical dosing), administered as a single agent and then in sequential combination with a glucosepane-targeted intervention (synthetic glucosepane-cleaving small molecule or bacterially derived enzymatic candidate from Spiegel lab chemical biology pipeline), is applied to aged male and female C57BL/6J mice (22–24 months, both sexes), with crosslink-type-specific aortic biochemistry measured in parallel with non-invasive Doppler pulse wave velocity (PWV),

THEN TRC4186 monotherapy will produce a statistically significant but mechanistically incomplete reduction in aortic PWV (~15–25% decrease from aged-vehicle baseline, consistent with partial crosslink reversal), and post-mortem aortic tissue will show selective reduction of methylglyoxal-derived crosslinks (MOLD, GOLD, quantified by LC-MS) with no significant change in glucosepane abundance (quantified by immunoassay or LC-MS/MS), and the residual PWV elevation above young-reference values will be positively correlated with remaining glucosepane burden,

BECAUSE the following causal chain is operative:

1. TRC4186 retains the N-phenacylthiazolium pharmacophore of alagebrium (ALT-711) and acts by nucleophilic attack at the C2 position of the thiazolium ring on α-dicarbonyl crosslink structures, theoretically cleaving C–C bonds in MOLD and GOLD adducts formed from methylglyoxal condensation with lysine residues on aortic collagen — (thiazolium C2 nucleophile cleaves alpha-diketone crosslinks)[Deshpande et al., Cardiovascular Diabetol

IF a tri-engineered nuclear backup construct — combining (1) a synthetic "super-import" N-terminal MTS derived from the ATP5G1 presequence augmented with positively charged lysine/arginine residues to increase TOM20 affinity, (2) a hydrophobicity-reduced, codon-optimized MT-ND4 coding sequence in which transmembrane helix residues are minimally substituted with isosteric but less hydrophobic alternatives (e.g., leucine→valine swaps at non-critical packing positions, identified computationally), and (3) a 3'UTR cis-acting mitochondrial surface localization element (MSLE) derived from the yeast ATM1 or mammalian TOMM40 3'UTR to anchor ribosomal translation to the mitochondrial outer membrane — is packaged into a self-complementary AAV2 (scAAV2) vector and delivered intravitreally to aged (20–24 month) male C57BL/6 mice,

THEN the following measurable outcomes will be observed compared to aged controls injected with a standard scAAV2-ND4 construct (analogous to GS010/Lumevoq design with COX10-MTS and no 3'UTR localization element):

• ≥40% greater import efficiency of recombinant ND4 protein into the mitochondrial inner membrane fraction (quantified by proteinase K protection assay and western blot of fractionated retinal tissue),
• ≥25% restoration of retinal Complex I activity (NADH-ubiquinone oxidoreductase activity assay, rotenone-sensitive, in isolated retinal mitochondria),
• Statistically significant preservation of RGC layer thickness (≥15% more cells versus aged vehicle control, measured by optical coherence tomography [OCT] and RBPMS immuno

Background

Musculoskeletal ultrasound (MSUS) has emerged as a sensitive tool for detecting subclinical synovitis in rheumatoid arthritis, outperforming clinical examination in identifying residual disease activity during apparent remission. However, OMERACT-EULAR scoring remains operator-dependent (κ = 0.59–0.78 inter-reader), limiting its utility for treat-to-target monitoring. Deep learning approaches require large annotated datasets that individual centers cannot provide due to privacy regulations (GDPR, HIPAA, LFPDPPP) and institutional data governance.

Hypothesis

A federated self-supervised vision transformer (ViT) pre-trained via masked autoencoder (MAE) reconstruction on unlabeled MSUS B-mode and power Doppler images across ≥10 rheumatology centers — without any raw image leaving institutional boundaries — will achieve:

1. Subclinical synovitis detection sensitivity >90% (vs. histological gold standard on available biopsy subsets) in patients meeting Boolean/SDAI remission criteria
2. Inter-center generalization with AUROC >0.88 on held-out external validation, exceeding single-center supervised models by >8 percentage points
3. Prediction of radiographic progression at 12 months (ΔSharp/van der Heijde ≥5) with C-statistic >0.80 when combined with baseline CRP and anti-CCP titer

Rationale

• Self-supervised MAE pre-training eliminates the annotation bottleneck: the model learns ultrasound tissue representations from reconstruction loss alone, requiring only downstream fine-tuning on smaller labeled sets
• Federated averaging (FedAvg with dif

IF young-donor (8–12 week) C57BL/6J HSC transplantation (as performed in RMR1) is combined with serial post-transplant clonal surveillance using a cost-effective, scalable error-corrected amplicon sequencing panel targeting canonical CHIP driver loci (Tet2, Dnmt3a, Asxl1, Jak2) at 3-month intervals, AND any clone exceeding 2% variant allele frequency (VAF) triggers targeted pharmacological elimination via cell-permeable α-ketoglutarate (αKG; 1–2 g/kg/day oral supplementation) combined with a sub-myeloablative dose of the hypomethylating agent decitabine (0.1 mg/kg i.p., 5-day cycle) to selectively re-sensitize epigenetically altered mutant clones to apoptosis while sparing wild-type HSCs,

THEN aged (22–24 month) C57BL/6J recipient mice will maintain ≥90% wild-type clonal composition in peripheral blood and bone marrow HSC compartment (measured by VAF ≤2% at all surveilled loci) through 6 months post-transplant, with preservation of multilineage output, reduction in clonal diversity loss (Shannon entropy), and suppression of pro-inflammatory myeloid skewing (IL-6, IL-1β plasma levels), as compared to RMR1 HSC-transplant-only controls receiving no post-transplant clonal intervention,

BECAUSE:

1. Young HSC grafts reconstituting an aged bone marrow niche are exposed to an inflammatory, TGF-β-rich, and metabolically altered microenvironment that historically selects for Tet2- and Dnmt3a-mutant clones with fitness advantages; surveillance using a scalable CHIP assay enables early detection of emergent clones before they dominate the graft (Cost-effective and sca

IF sub-maximal, dose-split dual delivery of TFEB and TFE3 — specifically, AAV8-ApoE-hAAT-TFEB (targeting ~40–50% of maximal TFEB transcriptional output based on titrated viral dose) co-administered with AAV8-ApoE-hAAT-TFE3 (similarly titrated to ~40–50% maximal TFE3 output), delivered by tail-vein injection at a combined titer of 2×10¹¹ vg per vector in 24-month-old male C57BL/6J mice,

THEN hepatic lipofuscin burden (measured by autofluorescence intensity per unit area by confocal imaging of liver sections at 488 nm excitation and by HPLC-fluorescence quantification of bis-retinoid lipofuscin components) will be reduced by ≥30% relative to untreated aged controls and by ≥15% relative to single-agent TFEB-alone controls at equivalent total transcriptional drive, AND hepatocellular transformation markers (Ki67 index, β-catenin nuclear translocation frequency, serum AFP, and liver-to-body-weight ratio) will be statistically non-inferior to young reference animals and significantly lower than mice receiving single-agent TFEB at full dose,

BECAUSE the following mechanistic chain operates:

1. TFEB is a master activator of the Coordinated Lysosomal Expression and Regulation (CLEAR) gene network, and its genetic or pharmacological activation upregulates lysosomal biogenesis and autophagic flux, enabling degradation of aggregated and oxidized cargo (TFEB activates CLEAR network and clears aggregated protein cargo)[https://doi.org/10.1371/journal.pone.0120819]. The same CLEAR network machinery is required for lipofuscin partial solubilization and lysosomal routing, establishing th

Hypothesis

We propose that equivariant graph neural networks (E(3)-GNNs) operating on autoantigen tertiary structures — specifically citrullinated vimentin, α-enolase, and fibrinogen — combined with learned HLA-DRB1 shared epitope allele embeddings, can predict which specific citrullinated peptide epitopes will elicit autoantibody responses in genetically susceptible individuals 12–36 months before ACPA seroconversion.

Background and Rationale

Current preclinical RA prediction relies on aggregate ACPA positivity, ignoring the sequential, epitope-specific nature of autoantibody spreading. The "epitope spreading" phenomenon — where immune responses progressively target additional citrullinated peptides — follows non-random patterns likely governed by (1) structural accessibility of citrullinated residues on native protein surfaces, (2) HLA-peptide binding affinity determined by shared epitope geometry, and (3) molecular mimicry with mucosal pathogen-derived peptides.

E(3)-equivariant GNNs preserve rotational and translational symmetries of protein structures, enabling physically meaningful representation learning over atomic coordinates. By encoding citrullination sites as node-level perturbations on AlphaFold2-predicted autoantigen structures and conditioning on HLA-DRB1 allele-specific binding groove geometries, the model can learn structure-function relationships governing immunodominant epitope selection.

Testable Predictions

1. Primary: E(3)-GNN epitope vulnerability scores will predict the temporal order of ACPA fine-specificity seroconversion (anti-C